• About Adlai Nortye

    Adlai Nortye

    Adlai Nortye is a global clinical-stage biopharmaceutical company that is developing differentiated, innovative immuno-oncology medicines. Adlai Nortye focuses on discovering and developing important new treatments for cancer with a mission to improve patient lives by identifying and developing differentiated innovative medicines that help people live better, live longer. Through close collaborations with global partners, Adlai Nortye have successfully positioned itself in the field of immuno-oncology and have several programs ongoing from early pre-clinical to phase III ready.

    Development History

    "Sinopep Pharmaceutical" was established in 2004.

    The fund from Science and Technology Ministry in 2009.

    Recognized as a “National High-tech Enterprises” in 2009.

    The 11th Polypeptide Technology Application Award in 2010.

    Shareholding system reform and renamed “Adlai Nortye Biopharma” in 2016.

    Listed on NEEQ in Feb 21, 2017. (Stock Code:870946)

    Terminated a listing on NEEQ in Mar, 2018.

    Raising $53 million in Series B Round of financing in June, 2018.

    Opened the new USA headquarters  in New Jersey in Sept. 25, 2018.